GlassScriptPhysician profile
Dana B Milligan
NPI 1235565367
$1,970.29
in general payments reported to CMS, 2019-2025
22 companies · $753 in 2025
The $753 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $356 · 2022: $187 · 2023: $218 · 2024: $456 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.40 | 2021-2025 | |
| Lilly USA, LLC | $210.84 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $199.82 | 2021-2025 | Evenity, Prolia |
| Novo Nordisk INC | $126.83 | 2022-2025 | Wegovy, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $73.50 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $67.87 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $66.28 | 2024-2025 | Fanapt |
| Novartis Pharmaceuticals Corporation | $65.65 | 2022-2023 | |
| Pfizer INC. | $59.55 | 2025 | |
| Acadia Pharmaceuticals INC | $59.37 | 2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $50.48 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $49.94 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $46.36 | 2025 | Voquezna |
| Axsome Therapeutics, INC. | $41.18 | 2024-2025 | Auvelity |
| Corcept Therapeutics | $40.22 | 2025 | Korlym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.16 | 2022-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $37.68 | 2021 | |
| Lundbeck LLC | $36.46 | 2025 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $33.18 | 2021 | |
| Covis Pharma Gmbh | $30.59 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.42 | 2025 | Dupixent |
| Sunovion Pharmaceuticals INC. | $21.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Milligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.